NRIP3 / Nuclear receptor-interacting protein 3 · IHC design guide

Design Immunohistochemistry for NRIP3

Plan chromogenic IHC on paraffin sections with the catalog antibody at 1:100–1:300 (datasheet A17131). Use Leydig cells as a positive reference and assess follicle and adrenal cortical cell staining (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for NRIP3 (IHC for NRIP3): expected localisation Tissue subcellular pattern not established (HPA tissue IHC), antibody A17131, validated IHC image, and IHC protocol steps — Printable **NRIP3** IHC protocol sheet — expected localisation Tissue subcellular pattern not established (HPA tissue IHC), antibody A17131, controls and protocol steps. Open the full NRIP3 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

NRIP3 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Tissue subcellular pattern not established (HPA tissue IHC)
	Staining pattern	High in Leydig cells; medium in follicle and zona fasciculata cells (HPA tissue IHC)
	Antigen retrieval	Tris-EDTA pH 9.0 HIER, heat-mediated (datasheet A17131)
	Positive control ⓘ	Adrenal gland+2 more · see all
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections (standard IHC practice; not target-specific). Selected-image fixative and duration unreported (datasheet A17131); verify before use.
	Caveat	Catalog text mentions BIVM; verify NRIP3 specificity (datasheet A17131)
	Regulation	No expression regulator reported (UniProt)
	Isoform / epitope	No isoforms or cleavage; no TM-defined epitope side (UniProt)

Section 1

Recommended NRIP3 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet: A17131) is accompanied by one published protocol for human ESCC tissue (PMC7445249).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human tonsil tissue; fixative not specified (datasheet A17131)
Fixation	Image fixative and duration unreported (datasheet A17131); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Tris-EDTA pH 9.0 (datasheet A17131); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-NRIP3, 1:100-1:300 (datasheet A17131)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	NRIP3-positive staining in cells in zona fasciculata of adrenal gland (HPA tissue IHC: Medium). HPA tissue profile: Expression in Leydig cells, ovarian follicles and adrenal cortical cells. No signal in the no-primary control.

💡Decision noteTry heat-mediated Tris-EDTA retrieval at pH 9.0 first (datasheet: A17131); the published ESCC method reports antigen retrieval without specifying its conditions (PMC7445249).

Section 2

What Is the Expected NRIP3 Staining Pattern?

NRIP3 is reported in the cytosol by ICC-IF (HPA: approved cytosol); UniProt does not annotate its subcellular location and reports no transmembrane segment (UniProt Q9NQ35 topology). In tissue IHC, expect staining in Leydig cells, ovarian follicle cells and adrenal zona fasciculata cells (HPA: tissue IHC). The tissue profile is Approved, pending external verification (HPA: reliability).

What am I looking at on my slide?
Leydig cells stain strongly; follicle and zona fasciculata cells stain moderately.	This matches the reported tissue distribution (HPA: High in Leydig cells; Medium in follicle and zona fasciculata cells). Judge the named cell populations within each section; a whole-section average can obscure their staining (standard IHC practice). HPA labels the tissue profile Approved but pending external verification (HPA: reliability).
Signal is mainly nuclear, membranous or extracellular in an otherwise plausible positive tissue.	These compartments differ from the approved cytosolic ICC-IF localization (HPA: subcellular). Treat the pattern as suspect and check morphology, counterstain and detection controls (standard IHC practice). The ICC-IF localization is a useful comparison, but it does not establish compartment-level validation for tissue IHC; UniProt lists no location (UniProt Q9NQ35).
Strong staining appears in adipocytes or appendix glandular cells while expected positive cells also stain.	HPA reports NRIP3 as Not detected in those cell populations (HPA: tissue IHC). Consider antibody cross-reactivity or endogenous detection activity, then compare with a reagent-omission control (standard IHC practice). A Not detected entry describes the reported HPA observation; it is not proof that every specimen must be completely blank.
Brown signal spreads through stroma or across many unrelated cell types without clear cell boundaries.	This is less convincing than cell-associated staining in the reported positive populations (HPA: tissue IHC). Diffuse staining may reflect nonspecific reagent binding, residual detection activity or section artefact (standard IHC practice). Assess an adjacent control section before assigning the signal to NRIP3.
No signal appears in a well-preserved testis section, including identifiable Leydig cells.	That conflicts with HPA's High Leydig-cell observation (HPA: tissue IHC). First confirm that the relevant cells are present, then review the catalog antibody's IHC-P instructions and the run's positive and negative controls (standard IHC practice). One failed section cannot establish that NRIP3 is absent.

💡Expected NRIP3 appearanceCall a section positive when identifiable Leydig cells show High staining or follicle or zona fasciculata cells show Medium staining (HPA: tissue IHC); cytosolic signal is consistent with approved ICC-IF localization (HPA: subcellular), whereas dominant nuclear or widespread unrelated-cell staining warrants investigation (standard IHC practice).

How each factor affects the staining
Tissue and cell selection	Testis Leydig cells provide the strongest reported tissue IHC signal; ovarian follicle and adrenal zona fasciculata cells provide Medium examples (HPA: tissue IHC). Choose a section with identifiable target cells before treating a blank field as a negative result (standard IHC practice).
Assay-specific antibody validation	HPA072961 is Approved for IHC, while HPA058827 is Approved for ICC and has no listed IHC status (HPA: antibodies). Approval in one assay does not transfer to the other. The tissue IHC profile remains pending external verification (HPA: reliability).
Compartment evidence	Cytosol is the approved ICC-IF location, with images listed for SiHa and U2OS (HPA: subcellular). UniProt does not annotate localization (UniProt Q9NQ35). Use cytosolic distribution as a consistency check in IHC, with that assay distinction visible in the interpretation.
Topology and processing	UniProt reports no transmembrane segment, signal peptide, propeptide, annotated glycosylation sites or isoforms; it lists a single 1–241 chain (UniProt Q9NQ35). These annotations offer no basis to predict a membrane pattern, shedding-dependent staining or isoform-specific differences. They also provide no target-specific antigen-retrieval or fixation guidance.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Testis control is blank in the Leydig-cell region.	The section may lack identifiable Leydig cells, or the IHC run may have failed (HPA: High in Leydig cells; standard IHC practice).	Confirm cell identity and section quality, then check the catalog antibody's IHC-P instructions, detection reagents and run controls (standard IHC practice). Do not infer NRIP3 absence from this run.
Follicle or adrenal staining looks weaker than the testis control.	HPA reports Medium staining in follicle and zona fasciculata cells, versus High in Leydig cells (HPA: tissue IHC).	Score each named cell population against its own reported level and section morphology (HPA: tissue IHC; standard IHC practice). Check run controls before treating a weaker positive as a failure.
Signal is dominant in nuclei or along membranes.	That distribution conflicts with approved cytosolic ICC-IF localization (HPA: subcellular); its cause is unresolved from the supplied evidence.	Review cell boundaries and counterstain, then compare reagent-omission and positive controls (standard IHC practice). Report that the compartment reference comes from ICC-IF, not tissue IHC (HPA: subcellular).
Adipocytes or appendix glandular cells stain strongly.	Both are reported Not detected by HPA tissue IHC; cross-reactivity or endogenous detection activity is possible (HPA: tissue IHC; standard IHC practice).	Inspect a reagent-omission control and assess whether the signal follows tissue structures or pools outside cells (standard IHC practice). Interpret these populations relative to the reported HPA observations.
Diffuse brown background obscures positive cells.	Nonspecific binding or residual endogenous detection activity can obscure chromogenic IHC (standard IHC practice).	Compare control sections, review blocking and detection steps, and assess whether clear cell-associated signal remains in a reported positive population (standard IHC practice; HPA: tissue IHC).
IF/ICC question: should a cytosolic signal match this IHC result?	HPA approves cytosolic localization in ICC-IF, but its listed ICC-approved and IHC-approved antibodies are different (HPA: subcellular; HPA: antibodies).	A cytosolic IF/ICC signal is consistent with HPA's localization; assess it under the separate IF/ICC guide and its own antibody validation (HPA: subcellular; HPA: antibodies). Do not transfer the tissue IHC intensity ratings directly to cultured cells.

Source: UniProt Q9NQ35 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing NRIP3 staining

Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 30min).

A17131 · IHCImmunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was use

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000175352-NRIP3/tissue/cerebral+cortex#imid_20707016

HPA · Adrenal glandHuman Protein Atlas IHC, Adrenal gland. Source: https://www.proteinatlas.org/ENSG00000175352-NRIP3/tissue/adrenal+gland#imid_1246

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000175352-NRIP3/tissue/colon#imid_20706646

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000175352-NRIP3/tissue/liver#imid_20706663

HPA · ICC-IF SiHaHuman Protein Atlas immunofluorescence, SiHa, antibody HPA058827; green = NRIP3, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for NRIP3 IHC & IF

🧪Run testis first and look for staining in Leydig cells (HPA: High in Leydig cells). Use adipose tissue as a negative comparator (HPA: Not detected in adipocytes); on the testis slide, score non-Leydig cells as internal negatives only if they remain unstained, since the supplied HPA rows do not assign them a negative level.

Positive control tissue: Adrenal gland (Cells in zona fasciculata, HPA Medium)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show NRIP3 in SiHa, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).

Technical controls: Include a no-primary (secondary-only) control, a host-species- and clonality-matched isotype control, and NRIP3-knockout tissue if available as a biological negative (standard IHC practice). Block endogenous peroxidase for chromogenic detection, and check testis pigment against the negative controls before scoring Leydig-cell signal (standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported; the selected paraffin-section caption does not state its fixative (A17131 caption: fixative not stated). The caption uses Tris-EDTA at pH 9.0 for retrieval and a 1:200 primary dilution overnight at 4 °C, but does not establish whether NRIP3 staining depends on that retrieval condition (A17131 caption). The supplied evidence does not establish that frozen sections or IF are easier; HPA reports cytosolic ICC-IF localisation in SiHa and U2OS (HPA: Cytosol, approved), while testis pigment can complicate chromogenic scoring (standard IHC practice).

HPA tissue IHC evidence for NRIP3

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Cells in zona fasciculata	Medium	Protein (IHC)	HPA →
Testis	Leydig cells	High	Protein (IHC)	HPA →
Ovary	Follicle cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced NRIP3 IHC Tips

Troubleshoot NRIP3 staining in paraffin sections by checking retrieval, cell identity and cytosolic localisation against the available tissue evidence.

How should I retrieve NRIP3 in paraffin sections with weak staining?

Start with heat-mediated retrieval in Tris-EDTA at pH 9.0 (datasheet A17131). The selected antibody’s paraffin-section tonsil image used this buffer and a 1:200 primary dilution incubated at 4°C overnight (caption A17131), giving a documented starting condition for IHC. Run a known NRIP3-positive cell population, such as testicular Leydig cells, alongside the problem section (HPA: High in Leydig cells), and compare staining after matched retrieval runs (general IHC practice). If staining remains weak, vary heating time or trial another retrieval buffer as a fallback, while checking tissue preservation and background in parallel (general IHC practice).

Could fixation explain weak or patchy NRIP3 staining?

Target-specific fixation sensitivity is unknown: the selected paraffin-section caption does not state a fixative (caption A17131). Record the actual fixative, fixation duration and time before processing for each specimen, then compare sections processed together under identical retrieval and detection conditions (general IHC practice). Overfixation and uneven fixation can reduce antigen accessibility or produce patchy staining in IHC generally, but those effects have not been established specifically for NRIP3 here (general IHC practice; caption A17131). Use the documented Tris-EDTA pH 9.0 retrieval first (datasheet A17131), and interpret differences only after checking morphology, section adherence and run controls (general IHC practice).

Which subcellular pattern should count as NRIP3 staining?

Score cytosolic staining as the expected pattern because NRIP3 is assigned an approved cytosolic location in cell imaging (HPA subcellular: Cytosol). UniProt supplies no subcellular annotation and reports no transmembrane segment, so a membrane-only pattern lacks support from this record (UniProt Q9NQ35). In chromogenic sections, assess the signal against a counterstain and cell boundaries, then compare the same compartment in negative controls and adjacent cell types (general IHC practice). A prominent nuclear-only deposit warrants checks for detection background and antibody specificity before it is counted as NRIP3 (HPA subcellular: Cytosol; general IHC practice).

How can epitope uncertainty affect NRIP3 IHC troubleshooting?

The supplied record lists a 241-amino-acid NRIP3 chain and no annotated isoforms, domains, glycosylation sites or modified residues (UniProt Q9NQ35). Those annotations do not identify the catalog antibody’s epitope or establish how processing exposes it, so document the antibody immunogen or mapped epitope if available (UniProt Q9NQ35; general IHC practice). Keep the catalog antibody’s Tris-EDTA pH 9.0 retrieval as the reference condition when comparing staining across sections (datasheet A17131). If an independent antibody or specificity control is available, compare cell identity and cytosolic pattern as well as staining intensity before attributing a discrepancy to an isoform (HPA subcellular: Cytosol; general IHC practice).

How can IF help assess an uncertain chromogenic NRIP3 result?

Use IF as a separate comparison to the paraffin-section IHC result: NRIP3 has an approved cytosolic location in cell imaging, including images from SiHa and U2OS cells (HPA subcellular). For tissue multiplexing, pair NRIP3 with a validated marker of the expected cell type, such as Leydig cells in testis, and assess both signals in the same cells (HPA tissue IHC: High in Leydig cells; general IF practice). Choose a fluorophore channel with low tissue autofluorescence, often toward the far red, and include single-stain controls (general IF practice). Because the expected signal is cytosolic and no transmembrane segment is annotated, optimise permeabilisation for access to an intracellular epitope (HPA subcellular: Cytosol; UniProt Q9NQ35; general IF practice).

How do I reduce diffuse brown background without losing NRIP3 signal?

First compare no-primary and detection-only controls with the stained section to locate background from the chromogenic workflow (general IHC practice). Check endogenous peroxidase blocking, blocking of nonspecific binding, washing and DAB development time; these are general IHC controls, not NRIP3-specific evidence (general IHC practice). The selected tonsil image used a 1:200 primary antibody overnight at 4°C and a 1:200 secondary for 30 minutes at room temperature (caption A17131). If diffuse deposit persists, adjust one step at a time and retain an expected positive cell population to distinguish cleaner staining from lost sensitivity (HPA tissue IHC: High in Leydig cells; general IHC practice).

How should I quantify NRIP3 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and cytosolic scoring rule before comparing sections, since HPA reports High staining in Leydig cells but Medium staining in ovarian follicle cells and adrenal zona fasciculata cells (HPA tissue IHC; HPA subcellular: Cytosol). Report the percentage of positive cells and staining intensity, or combine them as an H-score from 0 to 300 using intensity grades 0–3 (general IHC practice). Normalise to the number of evaluable cells in the specified compartment, and exclude folds, necrosis and section edges consistently (general IHC practice). Keep retrieval, detection and image settings matched, and report controls with each comparison (general IHC practice).

When is an apparent NRIP3-positive area likely to be artefact?

A convincing result places signal in the cytosol of a plausible cell population: HPA reports High staining in testicular Leydig cells and Medium staining in ovarian follicle and adrenal zona fasciculata cells (HPA tissue IHC; HPA subcellular: Cytosol). Treat isolated nuclear or membrane-only staining cautiously because the approved imaging location is cytosolic and no transmembrane segment is annotated (HPA subcellular: Cytosol; UniProt Q9NQ35). Edge deposits, necrotic areas and staining in no-primary controls suggest technical artefact; check endogenous peroxidase when using chromogenic detection (general IHC practice). HPA labels its tissue staining Approved while noting pending external verification, so confirm unexpected patterns with an independent specificity control (HPA tissue IHC; general IHC practice).

Boster reagents

Best NRIP3 / Nuclear receptor-interacting protein 3 IHC Antibodies

A17131 is listed for human and mouse IHC and IF (catalog: applications and reactivity), with a real IHC image from a paraffin-embedded human tonsil section (IHC image caption).

Real IHC data Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4° overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 30min).

Anti-NRIP3 Antibody

Cat # A17131

View product →

A17131 will render with an IHC image of paraffin-embedded human tonsil (IHC image caption). IF is a listed application, but no IF image is supplied (catalog: applications and IF image alts).

Which to pick: For tissue IHC, choose A17131, a rabbit polyclonal antibody with a paraffin-section IHC example (catalog: host; IHC image caption); the fixative is unreported (IHC image caption). For IF/ICC planning, A17131 lists IF but supplies no IF image or ICC validation (catalog: applications and IF image alts). For cross-species work, A17131 lists human and mouse reactivity, while its IHC image documents human tissue only (catalog: reactivity; IHC image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9NQ35 (NRIP3_HUMAN, Nuclear receptor-interacting protein 3).
Human Protein Atlas. NRIP3 tissue IHC expression (reliability: Approved).
Human Protein Atlas. NRIP3 subcellular location (ICC-IF): Localized to the cytosol..
Human Protein Atlas. NRIP3 antibody validation summary (2 antibodies).
NRIP3 upregulation confers resistance to chemoradiotherapy in ESCC via RTF2 removal by accelerating ubiquitination and degradation of RTF2. Oncogenesis 2020 — PMC7445249.
PubMed PMID:11528127 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:15489334 — UniProt-cited evidence.